Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.

Rhythm Biosciences Ltd. launched a new genetype colorectal cancer risk assessment clinical test that incorporates clinical ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...

The Chicago Bears are expected to battle it out for a member of the Denver Broncos' stellar defensive line this offseason.

Speaking of strawberries, Ponchatoula isn’t just the “Antique City”—it’s also proudly known as the “Strawberry Capital of the ...

Muscle memory is a commonly used term for motor skill acquisition and retention. Activities like cycling or swimming are good ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...